Coronary heart disease and stroke with aromatase inhibitor, tamoxifen, and menopausal hormone therapy use

Clinical Breast Cancer

Volumn 6, Issue SUPPL. 2, 2006, Pages

  Chlebowski, Rowan T ^a   Anderson, Garnet L ^b   Geller, Michelle ^a   Col, Nananda ^c  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c BROWN UNIVERSITY   (United States)

Author keywords

Cardiovascular disease; Cholesterol; Estrogen; Lipid profile; Progestin

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; CHOLESTEROL; CONJUGATED ESTROGEN; ESTROGEN; EXEMESTANE; GESTAGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LETROZOLE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEDROXYPROGESTERONE ACETATE; PLACEBO; TAMOXIFEN; TAMOXIFEN CITRATE; TRIACYLGLYCEROL; LIPID;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CARDIOVASCULAR DISEASE; CLINICAL PROTOCOL; CLINICAL TRIAL; COLORECTAL CANCER; CORONARY RISK; DEMENTIA; DRUG FATALITY; ENDOMETRIUM CANCER; HEART DEATH; HEART INFARCTION; HIP FRACTURE; HORMONAL THERAPY; HUMAN; HYPERTRIGLYCERIDEMIA; ISCHEMIC HEART DISEASE; LUNG EMBOLISM; MENOPAUSAL SYNDROME; META ANALYSIS; MONOTHERAPY; POSTMENOPAUSE; RANDOMIZATION; RISK ASSESSMENT; STROKE; SYSTEMATIC REVIEW; AGED; BLOOD; BREAST TUMOR; CEREBROVASCULAR ACCIDENT; CHEMICALLY INDUCED DISORDER; CORONARY ARTERY ATHEROSCLEROSIS; FEMALE; HORMONE SUBSTITUTION; MIDDLE AGED; REVIEW; RISK FACTOR;

AGED; AROMATASE INHIBITORS; BREAST NEOPLASMS; CEREBROVASCULAR ACCIDENT; CLINICAL TRIALS; CORONARY ARTERIOSCLEROSIS; DEMENTIA; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; LIPIDS; MIDDLE AGED; RISK FACTORS; TAMOXIFEN;

EID: 33645956519     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2006.s.005     Document Type: Article

References (61)

1. Early Breast Cancer Trialist' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 16-year survival: an overview of the randomized trials. Lancet 2005; 365:1687-1717.
2. Chlebowski RT, Col N, Winer EP, et al. American Society of Clinical Oncology Technology Assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. J Clin Oncol 2002; 20:3328-3343.
3. ATAC Trialist Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of five years adjuvant treatment for breast cancer. Lancet 2005; 365:60-62.
4. Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology Technology Assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 2005; 23:619-629.
5. Stampfer M, Colditz G. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991; 20:47-63.
6. Grady D, Rubin SB, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117:1016-1037.
7. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288:321-333.
8. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004; 291:1701-1712.
9. Chlebowski RT, Hendrix SL, Langer RD, et al. For the WHI Investigators. Estrogen plus progestin influence on breast cancer and mammography in healthy postmenopausal women: The Women's Health Initiative randomized trial. JAMA 2003; 289:3243-3253.
10. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003; 349:523-534.
11. Wassertheil-Smoller S, Hendrix SL, Limacher M, et al. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA 2003; 289:2673-2684.
12. Shumaker SA, Legault C, Kuller L, et al. For the Women's Health Initiative Memory Study Investigators. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women. Women's Health Initiative Memory Study. JAMA 2004; 291:2947-2958.
13. Howell A, Cuzick J. Vascular effects of aromatase inhibitors: data from clinical trials. J Steroid Biochem Mol Biol 2005; Epub ahead of print.
14. Esteva FJ, Hortobagyi GN. Comparative assessment of lipid effects of endocrine therapy for breast cancer: implications for cardiovascular disease prevention in postmenopausal women. Breast 2005; Epub ahead of print.
15. AHA/ACC Scientific Statement. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Assessment of cardiovascular risk. J Am Coll Cardiol 1999; 34:1348-1359.
16. AHA Council on Epidemiology and Prevention Case Definitions for Acute Coronary Heart Disease in Epidemiology and Clinical Research Studies. A statement from the AHA council on epidemiology and prevention; AHA statistics committee; World Heart Federation Council on Epidemiology and Prevention; the European Society of Cardiology Working Group on Epidemiology and Prevention; Centers for Disease Control and Prevention; and the National Heart, Lung, and Blood Institute. Circulation 2003; 108:2543.
17. Anderson KM, Odell PM, Wilson PW, et al. Cardiovascular disease risk profiles. Am Heart J 1991; 121:293-298.
18. Goss P, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early stage breast cancer. N Engl J Med 2003; 349:1793-1802.
19. Coombes R, Hall E, Gibson LJ, et al. For the InterGroup Exemestane Study. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004; 350:1081-1092.
20. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280:605-613.
21. Anderson GL, Manson J, Wallace R, et al. Implementation of the Women's Health Initiative study design. Ann Epidemiol 2003; 13:S5-S17.
22. Col NF, Pauker SG. Discrepancy between observational studies and randomized trials of menopausal hormone therapy: did expectations shape experience? Ann Intern Med 2003; 139:923-929.
23. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 2005; 97:1652-1662.
24. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/ progestin regimens on heart disease risk factors in postmeninopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995; 273:199-208.
25. Love RR, Wiebe DA, Newcomb PA, et al. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann Int Med 1991; 115:860-864.
26. Herrington DM, Klein KD. Effects of SERMs an important indicator of cardiovascular health: lipoprotein, hemostatic factors and endothelial function. Women's Health Issues 2001; 11:95-102.
27. Sawada S, Sato K. Effect of anastrozole and tamoxifen on serum lipid levels in Japanese postmenopausal women with early breast cancer. Breast Cancer Res Treat 2003; 82:(suppl 1)S31-S32 (Abstract #143).
28. Atalay G, Dirix L, Biganzoli L, et al. The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, "Randomised phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients". Ann Oncol 2004; 15:211-217.
29. Banerjee S, Smith IE, Folkerd L, et al. Comparative effects of anastrozole, tamoxifen alone and in combination on plasma lipids and bone-derived resorption during neoadjuvant therapy in the impact trial. Ann Oncol 2005; 16:1632-1638.
30. Hozumi Y, Kawano M, Saito T, et al. Effect of tamoxifen on serum lipid metabolism. J Clin Endocrinol Metab 1998; 83:1633-1635.
31. Kanel KT, Wolmark N, Thompson PD. Delayed severe hypertriglyceridemia from tamoxifen. N Engl J Med 1997; 337:281.
32. Herrington DM, Klein KP. Effects of SERMs on important indicators of cardiovascular health: lipoproteins, hemostatic factors, and endothelial function. Womens Health Issues 2001; 11:95-102.
33. McDonald CC, Alexander FE, Whyte BW, et al. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial. The Scottish Cancer Trials Breast Group. BMJ 1995; 311:977-980.
34. Wasan KM, Goss PE, Pritchard PH, et al. The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L). Ann Oncol 2005; 16:707-715.
35. Thurlimann B, Keshaviah A, Coates AS, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005; 353:2747-2757.
36. Markopoulos C, Polychronis A, Zobolas V, et al. The effect of exemestane on the lipidemic profile of postmenopausal early breast cancer patients: preliminary results of the TEAM Greek sub-study. Breast Canc Res Treat 2005; 93:61-66.
37. Markopoulos C, Chrissochou M, Michalidou A, et al. Effect of exemestane on the lipidemic profile of postmenopausal operable breast cancer patients following 5-7 years of adjuvant tamoxifen: preliminary results of the ATENA substudy. Anti-Cancer Drugs 2005; 16:879-883.
38. Bundred NJ. The effects of aromatase inhibitors on lipids and thrombosis. British J Ca 2005; 93(suppl 1):S23-S27.
39. Bushnell CD, Goldstein LB. Risk of ischemic stroke with tamoxifen treatment for breast cancer: a meta-analysis. Neurology 2004; 63:1230-1233.
40. Geiger AM, Fischberg GM, Chen W, et al. Stroke risk and tamoxifen therapy for breast cancer. J Natl Cancer Inst 2004; 96:1528-1536.
41. Braithwaite RS, Chlebowski RT, Lau J, et al. Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med 2003; 18:937-947.
42. Stewart HJ, Prescott RJ, Forrest AP. Scottish adjuvant tamoxifen trial: a randomized study updated to 15 years. J Natl Cancer Inst 2001; 93:456-462.
43. Reis SE, Costantino JP, Wickerham DL, et al. Cardiovascular effects of tamoxifen in women with and without heart disease: breast cancer prevention trial. National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial Investigators. J Natl Cancer Inst 2001; 93:16-21.
44. Cuzick J, Forbes J, Edwards R, et al. First results from the International Breast Cancer Intervention Study (IBIS): a randomized prevention trial. Lancet 2002; 360:817-824.
45. Geiger AM, Chen W, Bernstein L. Myocardial infarction risk and tamoxifen therapy for breast cancer. Br J Cancer 2005; 92:1614-1620.
46. Bradbury BD, Lash TL, Kaye JA, et al. Tamoxifen-treated breast carcinoma patients and the risk of acute myocardial infarction and newly-diagnosed angina. Cancer 2005; 103:1114-1121.
47. Nordenskjold B, Rosell J, Rutqvist LE, et al. Coronary heart disease mortality after 5 years of adjuvant tamoxifen therapy: results from a randomized trial. J Natl Cancer Inst 2005; 97:1609-1610.
48. McCloskey E, Eastell R, Hannon RA, et al. Initial results from the LEAP study: the first direct comparison of safety parameters between aromatase inhibitors (ALs) in healthy postmenopausal women. Breast Cancer Res Treat 2005; 94:5101.
49. Wojtacki J, Lesniewski-Kmak K, Pawlak W, et al. Anastrozole therapy and lipid profile: an update. Euro J Cancer 2004; 2(suppl 3):142 (Abstract # 297).
50. Dewar J, Nabholtz JM, Bonneterre J, et al. The effect of anastrozole (Arimidex) on serum lipids - a randomized comparison of anastrozole (AN) vs. tamoxifen (TAM) in postmenopausal women with advanced breast cancer. Presented at: 7th Nottingham International Breast Cancer Conference; September 19-21, 2001; Nottingham, United Kingdom. Abstract #47.
51. Elisaf MS, Bairaktari ET, Nicolaides C, et al. Effect of letrozole on the lipid profile in postmenopausal women with breast cancer. Eur J Cancer 2001; 37:1510-1513.
52. Harper-Wynne C, Ross G, Sacks N, et al. Effects ofthe aromatase inhibitor letrozole on normal breast epithelial cell proliferation and metabolic indices in postmenopausal women: a pilot study for breast cancer prevention. Cancer Epidemiol Biomarkers Prev 2002; 11:614-621.
53. Heshmati HM, Khosla S, Robins SP, et al. Role of low levels of endogenous estrogen in regulation of bone resorption in late postmenopausal women. J Bone Miner Res 2002; 17:172-178.
54. Lonning PE, Geisler J, Krag LE, et al. Effects of exemestane administered for 2 years versus placebo on bone mineral density bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol 2005; 23:5126-5137. Epub 2005.
55. Cuzick J. Aromatase inhibitors for breast cancer prevention. J Clin Oncol 2005; 23:1636-1643.
56. Howell A. ATAC trial update. Lancet 2005; 365:1225-1226.
57. Aman U, Buzdar J, Cuzick J. Anastrozole as an adjuvant endocrine treatment for postmenopusal patients with breast cancer: emerging data. Clin Cancer Res 2006; 12:1037s-1048s.
58. Nabholtz JM, Gligorov J. Comparison of cardiovascular (CV) safety profiles of aromatase inhibitors (AIs). Presented at: ECCO 13-The European Cancer Conference; October 30-November 3, 2005; Paris, France.
59. Jakesz R, Jonat W, Gnant M, et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after two years adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005; 366:455-462.
60. Schairer C, Mink PJ, Carroll L, et al. Probabilities of death from breast cancer and other causes among female breast cancer patients. J Natl Cancer Inst 2004; 96:1311-1321.
61. Howell A. Adjuvant aromatase inhibitors for breast cancer. Lancet 2005; 366:431-433.